摘要
二甲双胍在治疗高血糖与高胰岛素血症方面表现出的有效性、安全性和经济性,使其成为临床上2型糖尿病患者的首选治疗药物。大量的流行病学调查表明,糖尿病不仅与血管病变的发展有关,而且与多种恶性肿瘤的发生密切相关。同时,流行病学与临床观察显示二甲双胍降低多种肿瘤的发病率,改善合并2型糖尿病的肿瘤患者的预后并能提高生存率。此外,二甲双胍已经作为抗肿瘤药物应用于临床试验中。因此,二甲双胍有望成为一个新的肿瘤治疗药物或辅助抗肿瘤药物。本文对二甲双胍抗肿瘤的分子机制进行综述。
Metforminis the most commonly prescribed drug for type 2 diabetes mellitus as it is inexpensive, safe, and efficient in ameliorating hyperglycemia and hyperinsulinemia. Numerous epidemiological studies indicate that diabetic population is not only at increased risk of cardiovascular complications, but also at substantially higher risk of many forms of malignancies. Meanwhile, epidemiological and clinical observation studies have shown that metformin use reduces risk of cancer in patients with type 2 diabetes mellitus and improves prognosis and survival rate of the cancer patients. Furthermore, metformin has been used for cancer therapy in clinical trials. Thus, metformin is emerging as a new cancer therapy or adjuvant anticancer drugs. This review summarizes recent progress in studies of metformin use and its molecular mechanism.
出处
《药学学报》
CAS
CSCD
北大核心
2015年第10期1210-1216,共7页
Acta Pharmaceutica Sinica
基金
国家自然科学基金资助项目(81273580
81473280)
关键词
2型糖尿病
二甲双胍
单磷酸腺苷依赖的蛋白激酶
雷帕霉素靶蛋白
胰岛素
胰岛素样生长因子-1
多药耐药
type 2 diabetes mellitus
metformin
adenosine monophosphate activated protein kinase
mammalian target of rapamycin
insulin
insulin-like growth factor 1
mutidrug resistance
